Washington Trust Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Washington Trust Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8	Closed	-$874	–	791
2023 Q1	$874	Sell	8 -18	-69%	-$1.99K	﹤0.01%	762
2022 Q4	$2.96K	Sell	26 -263	-91%	-$21.8K	﹤0.01%	687
2022 Q3	$18K	Buy	289 +9	+3%	+$629	﹤0.01%	539
2022 Q2	$22K	Sell	280 -305	-52%	-$28.9K	﹤0.01%	529
2022 Q1	$61K	Buy	585 +11	+2%	+$1.07K	﹤0.01%	410
2021 Q4	$62K	Buy	+574	New	+$62.6K	﹤0.01%	437

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Washington Trust Advisors's HZNP Position: Q2 2023 in Review

Washington Trust Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 8 shares — an estimated $874 sold.

Washington Trust Advisors first reported a position in HZNP in Q4 2021 and held it in 6 quarters. The position peaked at $62K in Q4 2021. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Washington Trust Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Washington Trust Advisors sold 8 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $874.
Washington Trust Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 6 quarters.
Washington Trust Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $62K in Q4 2021.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Washington Trust Advisors's 13F filing for Q2 2023, filed 27 Jul 2023.